Skip to main content
Premium Trial:

Request an Annual Quote

Avi Nash, Jai Nagarkatti, Scott W. Binder

Premium

Sigma-Aldrich's board of directors elected Avi Nash as a director, the company said last week.

Nash currently heads a management consulting firm, Avi Nash LLC, launched in 2003. Prior to this, he was a partner at Goldman Sachs. He has worked at Booz, Allen & Hamilton and UOP.

The board also appointed Jai Nagarkatti, president and chief operating officer of the company since 2004, as president and chief executive officer to replace outgoing CEO David Harvey, who will remain chairman of the board.

Also elected to the board, Nagarkatti's appointment takes effect on Jan. 1, 2006.

Nagarkatti has been with Sigma-Aldrich for 29 years in R&D, production, operations and sales and marketing. He has a Master's degree in chemistry from Osmania University in Hyderabad, India, and a Ph.D. in organic chemistry from Texas A&M University.


Pathologist Scott W. Binder has joined CombiMatrix's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, as a member of its Scientific Advisory Board, Acacia Research said earlier this week.

A professor of clinical pathology and dermatology, chief of dermatopathology, and director of pathology outreach services at the David Geffen School of Medicine at UCLA, he is the founder and director of a dermatopathology fellowship training program in California.

Binder received his B.A. and M.D. from the University of Chicago Medical School, completed his residency at the Department of Pathology and Laboratory Medicine at UCLA, and was a fellow with at the Scripps Clinic and Research Institute in La Jolla, CA. He completed a preceptorship at New York University.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.